This study is checking if a new drug, **ziftomenib**, is safe and works well with other medicines for treating **acute myeloid leukemia (AML)**, a type of blood cancer. The study has three parts to see how ziftomenib can help people with certain genetic changes in their cancer. Some people might have been recently diagnosed, while others may not have responded to earlier treatments.

**Key Points:**

• **Study Duration and Visits:** The study is long-term; participants need regular visits for treatment and check-ups.
• **Eligibility:** Participants must have specific genetic changes and meet health requirements. They should not have certain other health problems or have had recent cancer treatments.
• **Safety Measures:** Men and women of childbearing age should use contraception during and after the study to prevent pregnancy.

Participants need to be in good general health, except for their cancer, and must follow safety rules, like avoiding certain vaccines and using protection if of childbearing potential. This study could help find better ways to treat AML, but it involves risks and requires a commitment.